Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
Ingresos
64
31
19
--
Crecimiento de los Ingresos (YoY)
--
63%
--
--
Costo de los ingresos
15
7
4
--
Utilidad bruta
49
24
15
--
Venta, General y Administración
70
32
21
--
Investigación y Desarrollo
9
4
3
--
Gastos de Operación
81
38
27
--
Otras Ingresos (Gastos) No Operativos
-14
0
1
--
Ingreso antes de impuestos
-46
-13
-9
91
Gasto por Impuesto a la Renta
0
0
0
28
Ingreso Neto
-46
-13
-9
62
Crecimiento de la Utilidad Neta
--
44%
-114.99%
--
Acciones en Circulación (Diluidas)
13.6
20.22
20.22
25.68
Cambio de Acciones (YoY)
--
0%
-21%
--
EPS (Diluido)
-3.4
-0.67
-0.44
2.43
Crecimiento de EPS
--
51%
-118%
--
Flujo de efectivo libre
-38
-18
-15
132
Flujo de efectivo libre por acción
--
--
--
--
Margen bruto
76.56%
77.41%
78.94%
--
Margen de operación
-50%
-45.16%
-57.89%
--
Margen de beneficio
-71.87%
-41.93%
-47.36%
--
Margen de flujo de caja libre
-59.37%
-58.06%
-78.94%
--
EBITDA
-29
-12
-10
--
Margen de EBITDA
-45.31%
-38.7%
-52.63%
--
D&A para EBITDA
3
2
1
3
EBIT
-32
-14
-11
--
Margen de EBIT
-50%
-45.16%
-57.89%
--
Tasa de Impuesto Efectiva
0%
0%
0%
30.76%
Estadísticas clave
Cierre Anterior
$13.72
Precio de apertura
$13.88
Rango del día
$12.91 - $13.88
Rango de 52 semanas
$10.92 - $17.94
Volumen
37.3K
Volumen promedio
59.8K
EPS (TTM)
-2.50
Rendimiento de dividendos
--
Cap. de mercado
$269.0M
¿Qué es SI?
Shoulder Innovations, Inc. manufactures medical devices. The company is headquartered in Grand Rapids, Michigan. The company went IPO on 2025-07-31. The firm offers advanced implant systems for shoulder arthroplasty. These systems are a core element of its ecosystem, designed to improve the core components of shoulder surgical care, preoperative planning, implant design and procedural efficiency, to benefit each stakeholder in the care chain. Its ecosystem is also comprised of enabling technologies, instrument systems, specialized support and surgeon-to-surgeon collaboration. Its advanced implants are comprised of its aTSA and rTSA systems, which are designed to address the needs of patients and surgeons, and include various, specifically designed components capable of an array of system configurations to facilitate different modes of operation (anatomic or reverse). Its InSet Glenoid technology serves as the foundation for its advanced implant systems and includes a novel InSet design.